---
title: "United-Guardian | 8-K: FY2026 Q1 Revenue: USD 2.872 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285729782.md"
datetime: "2026-05-08T13:02:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285729782.md)
  - [en](https://longbridge.com/en/news/285729782.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285729782.md)
---

# United-Guardian | 8-K: FY2026 Q1 Revenue: USD 2.872 M

Revenue: As of FY2026 Q1, the actual value is USD 2.872 M.

EPS: As of FY2026 Q1, the actual value is USD 0.18.

EBIT: As of FY2026 Q1, the actual value is USD 642.45 K.

#### Net Sales

United-Guardian, Inc.’s net sales increased to $2,872,222 in the first quarter of 2026, up from $2,481,127 in the first quarter of 2025, representing a 15.7% increase year-over-year.

#### Net Income

Net income for the first quarter of 2026 rose to $818,902, compared to $560,895 in the same period of 2025, marking a 46.0% increase.

#### Segment Revenue Performance

Pharmaceutical sales increased by 24% in the first quarter of 2026, primarily due to higher demand for Renacidin®. Sales of cosmetic ingredients grew by 21%, mainly driven by a 45% increase in purchases from Ashland Specialty Ingredients (ASI).

#### Operational Costs and Income

-   **Cost of Sales:** Increased to $1,447,789 in Q1 2026 from $1,123,076 in Q1 2025.
-   **Operating Expenses:** Rose to $666,963 in Q1 2026 from $632,735 in Q1 2025.
-   **Research and Development:** Slightly increased to $115,021 in Q1 2026 from $114,394 in Q1 2025.
-   **Total Costs and Expenses:** Amounted to $2,229,773 in Q1 2026, up from $1,870,205 in Q1 2025.
-   **Income from Operations:** Increased to $642,449 in Q1 2026 from $610,922 in Q1 2025.

#### Other Income

Total other income significantly increased to $390,689 in Q1 2026 from $97,037 in Q1 2025. This increase was substantially due to $303,133 in settlement income recognized from the contract manufacturer of Renacidin. Investment income decreased to $69,814 from $84,687, while net gain on marketable securities increased to $17,742 from $12,350.

#### Income Before Taxes and Provision for Income Taxes

Income before provision for income taxes was $1,033,138 in Q1 2026, up from $707,959 in Q1 2025. The provision for income taxes was $214,236 in Q1 2026, compared to $147,064 in Q1 2025.

#### Outlook

United-Guardian, Inc. is optimistic about continued sales increases in 2026. This outlook is driven by Ashland Specialty Ingredients resuming regular purchasing patterns, new distribution agreements, and an increased focus on expanding “natural” product lines. Additionally, ongoing efforts to boost outreach and market penetration for Renacidin are expected to contribute to growth.

### Related Stocks

- [UG.US](https://longbridge.com/en/quote/UG.US.md)

## Related News & Research

- [Zenas BioPharma Insider Bought Shares Worth $1,012,800, According to a Recent SEC Filing](https://longbridge.com/en/news/286872009.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [Americas Gold and Silver Reports Record Production and Sales in Q1 2026 as Execution on the Growth Plan Continues at Galena | USAS Stock News](https://longbridge.com/en/news/286470577.md)
- [Royce Small-Cap Trust (NYSE: RVT) as of Apr 30, 2026 | RVT Stock News](https://longbridge.com/en/news/287103750.md)